MedPath

Effectiveness of extended dose of tranexamic acid for 48 hours vs single dose perioperative tranexamic acid on reduction of blood loss after primary total knee arthroplasty: A randomized controlled trial

Phase 4
Conditions
Total knee replacement
Oral tranexamic acid
Registration Number
TCTR20190114001
Lead Sponsor
Faculty of Medicine, Prince of Songkla university
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending (Not yet recruiting)
Sex
All
Target Recruitment
94
Inclusion Criteria

Patients undergoing primary unilateral total knee arthroplasty
Diagnosis of primary osteoarthritis of knee
Age less than 85 years old

Exclusion Criteria

1.Previous surgery around the affected knee
2.Complex TKA requiring the use of stemmed prosthesis
3.Use of anticoagulant at the time of admission
4.Documented allergy to drug in the study
5.History of deep vein thrombosis or pulmonary embolism
6.Abnormal coagulation at admission
International normalized ration > 1.5
Partial thromboplastin time > 1.4x normal
Platelet < 50,000/microL
7.Abnormal liver function test
Aspartate transaminase/Alanine transaminase > 3x normal
Alkaline phosphatase > 5x normal
8.Calculated glomerular filtration rate < 30 mL/min
9.History of acute coronary syndrome or cerebrovascular accident in the past 12 months
10.Active cancer
11.Use of drug with interaction with Tranexamic acid; eg. Tretinoin, Estrogen, Oral contraceptive pill

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Total blood loss 72 hour ml
Secondary Outcome Measures
NameTimeMethod
Hb level 24 hr &#44; 72 hr g/L,Blood tranfusion 72 hr unit
© Copyright 2025. All Rights Reserved by MedPath